Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.fiercebiotech.com/biotech/gilead-s-5b-galapagos-black-hole-widens-as-pair-toss-out-phase-3-asset-after-flop
I know a drug that can fill the void.
Mo I think this is the reason for the jump.
https://www.msn.com/en-us/news/us/us-supreme-court-rebuffs-merck-appeal-in-hepatitis-c-patent-fight-with-gilead/ar-BB1cTqOS
Thanks again.
Thanks Tucaman!
$35!
I see what you mean. I guess we will find out next week if this was an outlier or the start of a trend.
Most pharmacies are open during the holidays with reduced hours. So amount filled for the day will be below average.
Aimt was bought at $34 from $11 one drug company. I highly doubt anything under $15.
Are you referring to colon cancer trial? Completion date is 2025 kinda far out.
I doubt Pfizer would be interested. They have moved towards drugs for oncology. I would love to see a deal with JnJ and Bayer. The each split the sale of Xarelto in there respective region. Their combined cash on hand is about 38b. Xarelto patent expires 2024 so this could fill the void. Wishful thinking of course.
CABG -Conary Artery Bypass Graft
So Teva has to file by today.
Did Teva get a extension for en banc?
Seems to me they are following Pfizer ad strategy in the early days. Know your numbers ads for Pfizer. Now we have true to your heart Amarin. Makes you wonder.
Best summary of lipitor's early days.
https://m.huffpost.com/us/entry/us_1176252
My thoughts exactly.
Reminds me when Bernie Sanders trashed Ariad about drug pricing. Months later buyout by Takeda.
Thanks Tucaman.
The lack of speculation or PR is part of price suppression. There are tons of bio companies running therapeutic trials for covid. So I don't think any PR would do much. IP or settlement news would be better catalyst.
Retail owns half of the shares. So price suppression should be no surprise.
Thanks Tuc!
With everything going on. Looks like it will be on the back burner for awhile.
Did some digging and found this article and a bill passed.
https://www.polsinelli.com/intelligence/ealert-proposed-bill-would-require-delisting#:~:text=The%20House%20of%20Representatives%20passed%20a%20bill%20on,district%20court.%20The%20House%20passed%20the%20bill%20unanimously.
Agreed. But until SC rules on this I will be wary.
Good article about infringement. Coincidentally written by Fish Richardson.
https://www.jdsupra.com/legalnews/generic-drug-labeling-and-induced-42320/
My thoughts exactly!
Pulled this up. Delisting of patents.
April 2011, FDA sent Teva a letter in response to the de-listing of certain GSK patents from the Orange Book, instructing Teva to “revise [its] label to include the information associated with the [de-listed] patent.” As a result, Teva amended its label in 2011 to be an essential copy of GSK’s full label, meaning it covered all three indications: hypertension, CHF, and post-MI LVD.
With this ruling I hope Amrn can negotiate a cap on marine sales. In return generics avoid infringement lawsuit.
Thanks bro!
Which is why I still own this. I've always felt Pfizer was a good fit. But recently I have been leaning towards Bayer or Bristol Myers. Lets hope this will actually happen sooner rather than later.
My break even is $8 after averaging up multiple times. So pissed as I sold Mdco and Aimt to add here. JT better come through soon as the market dips. I don't want to miss out again. What a royal mess this 4 year investment has become.
Anything below 10pps change it to OBVIOUS.
Here is a good article that might answer some questions.
https://corpgov.law.harvard.edu/2012/04/02/insider-trading-in-takeover-targets/
I am not in the doom and gloom camp. Worldwide statin revenue approaching 1T. Is it not feasible that lifetime sales will not be at least 2% (20B) of the pie. I expect a run up and premium based of that if a takeover happens.
Salt to the wounds.
Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion.
https://finance.yahoo.com/news/report-gilead-sciences-cancer-treatment-222217580.html
A while back I mentioned activist investor Alex Denner is who was needed on the board.
Here is brief detail about him.
https://endpts.com/activist-investor-alex-denner-in-the-spotlight-again-as-the-medicines-company-shrinks-its-board/
Nestle already owned 19% before the deal.